pdufa.bio

Veligrotug (VRDN-001)

Page updated ·next FDA decision on the calendar ·Data as of Oct 14, 2026 7:39 PM ET

Veligrotug (VRDN-001) is a Viridian Therapeutics Inc. program in thyroid Eye Disease (TED). The FDA approved it on Jun 26, 2026. 1 FDA decision on record below. Every date links its source.

VRDN catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

FDA approval tracked on pdufa.bio: thyroid Eye Disease (TED) (approved Jun 26, 2026). Earlier approvals may not be listed here; the FDA label is the full record. Sponsor: Viridian Therapeutics Inc. (VRDN). Approval record: Viridian states a PDUFA target action date of June 30, 2026 for veligrotug in thyroid eye disease, with the company describing itself as launch-ready. Market-cap tier at the time we tracked it: Small. We track 1 catalyst event for this program: 0 upcoming and 1 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

FDA decision · Jun 26, 2026 ✓ ApprovedVRDN

Specialist biotech funds holding VRDN, 13F for the quarter ended June 30, 2026

FundSharesValue at quarter endFiling
Avoro Capital Advisors2,500,000$45.9 millionfiled August 14, 2026
Baker Bros. Advisors2,383,025$43.8 millionfiled August 14, 2026
Perceptive Advisors581,980$10.7 millionfiled August 14, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is Veligrotug (VRDN-001)'s next FDA decision or readout?

No upcoming catalyst is on our calendar for Veligrotug (VRDN-001); 1 FDA decision is on record below.

What happened at Veligrotug (VRDN-001)'s most recent FDA decision?

On Jun 26, 2026 the FDA approved the application. The decision page carries the source document and the measured share-price reaction.

What is Veligrotug (VRDN-001) used for?

In our records Veligrotug (VRDN-001) is FDA-approved for thyroid Eye Disease (TED) (approved Jun 26, 2026). Other approved uses may not be tracked here; the FDA label is the full record.

Who makes Veligrotug (VRDN-001)?

Viridian Therapeutics Inc. (VRDN).

Has Veligrotug (VRDN-001) been approved by the FDA?

Yes. The FDA approved an application for Veligrotug (VRDN-001) on Jun 26, 2026; the decision page linked above carries the source.

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.